undamentalytics Newsletter

Edelman Joseph: insider trades

Director, 10% owner at 9 companies we cover. 16 open-market purchases and 5 sales not made under a pre-set plan, reported from July 24, 2013 to August 27, 2026.

Would copying Edelman Joseph’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 10 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on July 25, 2013 into $126 by November 2, 2026, −28.1% a year. The copy held shares only 56% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $30,671, +8.8% a year (the S&P 500 held throughout made $55,982, +13.9% a year). Beta against the index was 0.85. Twelve months after each report, the average purchase was −49.0% against the S&P 500 (median −42.5%), and 10% beat it. Measured from the trade date, the insider’s own timing, the average was −48.1%.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k$60.0k 2013201520172019202120232025 $56.0k$30.7k$126
Copying Edelman JosephS&P 500, same days investedS&P 500, held throughout $10,000 copying Edelman Joseph’s open-market purchases from July 25, 2013, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−28.1%
S&P 500, same days invested
+8.8% (held throughout +13.9%)
Time in shares
56%
Sharpe ratio (S&P 500)
−0.30 (0.74)
Biggest drop (S&P 500)
−99% (−34%)
Market sensitivity (beta)
0.85
Purchases copied
11

Trade by trade

Edelman Joseph: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 10 −28.1% −23.5% 0% 7 −7.50 <0.001 Strong evidence: behind
Purchases, 6 months after the report 10 −26.7% −15.4% 0% 7 −2.95 0.025 Some evidence: behind
Purchases, 12 months after the report 10 −49.0% −42.5% 10% 7 −2.91 0.027 Some evidence: behind
Purchases, 12 months after the trade 10 −48.1% −43.6% 10% 7 −2.71 0.035 Some evidence: behind
Sales, 3 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the trade 0 — — — — — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Aldeyra Therapeutics, Inc. ALDX —50October 28, 2015April 8, 2024
Adma Biologics, Inc. ADMA —12May 23, 2019September 30, 2021
Leonabio, Inc. LONA —30January 27, 2021December 29, 2023
Talphera, Inc. TLPH —11July 24, 2013September 30, 2016
Meiragtx Holdings plc MGTX —20August 20, 2019August 14, 2024
Solid Biosciences Inc. SLDB —20March 23, 2021February 21, 2025
Yarrow Bioscience, Inc. YARW —02May 7, 2021August 18, 2021
Verrica Pharmaceuticals Inc. VRCA —10December 29, 2023December 29, 2023
Immatics N.V. IMTX —10August 27, 2026August 27, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
August 27, 2026August 26, 2026 IMTX Purchase $7,499,991 not yetnot yetnot yet
February 21, 2025February 19, 2025 SLDB Purchase $20,150,000 −46.9%−4.3%−25.5%
August 14, 2024August 12, 2024 MGTX Purchase $5,000,000 not yetnot yetnot yet
April 8, 2024April 4, 2024 ALDX Purchase $833,867 not yetnot yetnot yet
December 29, 2023December 27, 2023 VRCA Purchase $2,305,132 −19.8%−115.0%−116.9%
December 29, 2023December 27, 2023 LONA Purchase $1,462,895 not yetnot yetnot yet
August 10, 2022August 8, 2022 ALDX Purchase $702,280 −15.3%+1.3%−4.4%
August 8, 2022August 4, 2022 ALDX Purchase $586,767 −21.3%−7.9%+10.1%
July 1, 2022June 29, 2022 LONA Purchase $4,100,372 not yetnot yetnot yet
September 30, 2021September 28, 2021 ADMA Sale $299,236 not yetnot yetnot yet
September 28, 2021September 23, 2021 ADMA Sale $990,600 not yetnot yetnot yet
August 18, 2021August 16, 2021 YARW Sale $435,000 not yetnot yetnot yet
May 7, 2021May 6, 2021 YARW Sale $3,670,000 not yetnot yetnot yet
March 23, 2021March 23, 2021 SLDB Purchase $14,999,996 −36.8%−92.6%−93.5%
January 27, 2021January 25, 2021 LONA Purchase $6,999,998 −21.0%−69.0%−66.3%
January 21, 2021January 19, 2021 ALDX Purchase $13,000,000 −23.0%−89.5%−95.8%
August 20, 2019August 12, 2019 MGTX Purchase $9,999,978 −34.3%−55.0%−53.7%
May 23, 2019May 21, 2019 ADMA Purchase $16,000,000 not yetnot yetnot yet
September 30, 2016September 28, 2016 TLPH Sale $849,564 not yetnot yetnot yet
October 28, 2015October 26, 2015 ALDX Purchase $323,000 −24.1%−28.3%−1.8%
July 24, 2013July 23, 2013 TLPH Purchase $9,902,500 −38.8%−30.1%−33.5%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Edelman Joseph traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.